Stock News - 4D Molecular Therapeutics, Inc. $FDMT

Latest Stock News for $FDMT
4D Molecular Therapeutics Appoints Kristian Humer as Principal Accounting Officer

Expected Stock impact: Slightly Positive
2026-03-30 22:29:28
4D Molecular Therapeutics Reports Strong Financial Results and Operational Milestones for 2025

Expected Stock impact: Noticeably Positive
2026-03-18 20:11:18